Laddar...

Pharmacodynamic Properties of Subcutaneous Immunoglobulin in Myasthenia Gravis: Sub-analyses From an Open-Label Trial

Background: We previously reported an open-label prospective trial of subcutaneous immunoglobulin (SCIg) in mild to moderate exacerbations of myasthenia gravis (MG). The effective dose of SCIg in MG and whether measured immunoglobulin G (IgG) levels correlated with measures of disease burden were no...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Front Neurol
Huvudupphovsmän: Putko, Brendan N., Beecher, Grayson, Siddiqi, Zaeem A.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Frontiers Media S.A. 2020
Ämnen:
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7477386/
https://ncbi.nlm.nih.gov/pubmed/32982936
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2020.00921
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!